Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPERION: Neoadjuvant Pembrolizumab + Chemo in ESCC
NCT05281003Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2023
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fudan University. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05281003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281003.